Jon Hesby and Dennis Fournogerakis on how to maximize post-merger synergies

Share on facebook
Share on twitter
Share on linkedin

As large pharma companies face diminishing pipelines, they often look to acquire emerging pharma companies with promising therapies. While there are benefits to this approach, companies must answer five questions to ensure they maximize efficiencies and launch products successfully after an acquisition. Partner Jon Hesby and Manager Dennis Fournogerakis describe the keys to post-acquisition product launches in this cover story in PM360.